HUPO 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Pharma and biotech companies at HUPO 2026

Sep 27 – Oct 1, 2026 Singapore ~1.8k attendees Website

12 pharma and biotech companies are at HUPO 2026 — 17 presentations on the program. Most represented: Alkahest (3 on the program), Immatics (3 on the program), Immunocore (2 on the program). 2 of them have their own page in this guide. As of Sep 25, 2026.

All 393 organizations at HUPO 2026 →

Showing 1–12 of 12 organizations

Organization	HUPO 2026 Attendance
Alkahest San Carlos, CA
alkahest.com Biotech Grifols-owned biotech developing plasma-based therapies for age-related diseases, with large-scale plasma proteomics research.	Talk Tue Sep 29 4:15pm–5:20pm Part of Advancements in Large Scale Proteomics Unlocking Population-Scale Longitudinal Plasma Proteomics Profiling For Early Disease Detection Nicoll 2-3 Methods Collaborators: Stanford University Talk Wed Sep 30 10:30am–12:00pm Part of Proteomics in Human Disease - Aging Longitudinal Deep Plasma Proteomics Reveals Early Biomarkers of Parkinson’s Disease and Molecular Trajectories from its Preclinical to Clinical Phases Room 331 Clinical Collaborators: Stanford University Workshop Wed Sep 30 12:15pm–1:15pm Illumina Lunch Seminar - Decoding Human Biology Through Proteomics: From Population Cohorts to Molecular Mechanisms Workshop hosted by Illumina Room 334-336 Clinical Poster Wed Sep 30 1:15pm–3:00pm Part of Poster session 3 Disentangling Biological and Non-Biological Drivers of Proteomic Signals for Robust Biomarker Discovery in Large-Scale Plasma Proteomics Studies Board PS03.010 Clinical · AI & data Collaborators: Stanford University Poster Wed Sep 30 1:15pm–3:00pm Part of Poster session 3 Biological Signal Detection in Large Scale Plasma Proteomics Is Shaped by Study Design and Platform Strategy Board PS03.017 Clinical · Methods Collaborators: Stanford University
Immatics Tübingen, Germany
immatics.com Biotech Clinical-stage biotech developing T cell receptor-based cancer immunotherapies, using immunopeptidomics to find tumour targets.	Talk Mon Sep 28 10:30am–12:00pm Part of Immunopeptidomics Comprehensive Profiling of HLA class II Immunopeptidomes to Discover Targets for Autoimmune Diseases Room 334-336 Clinical Poster Wed Sep 30 1:15pm–3:00pm Part of Poster session 3 Toward Spatially Resolved Immunopeptidomics: LCM and HybridDIA Unlock the Tumor Microenvironment Board PS03.044 Single-cell · Clinical Poster Wed Sep 30 1:15pm–3:00pm Part of Poster session 3 HybridDIA Enables Single-Shot Quantitative Immunopeptidomics for Low-Input and Spatially Resolved Applications Board PS03.075a Methods · Single-cell
Immunocore Abingdon, United Kingdom
immunocore.com Biotech Commercial-stage biotech developing T cell receptor bispecific immunotherapies for cancer, infectious and autoimmune diseases.	Poster Wed Sep 30 1:15pm–3:00pm Part of Poster session 3 Miniaturized Immunopeptidomics Workflow for Target Discovery and Validation from Scarce Samples Board PS03.045 Methods · Clinical Poster Wed Sep 30 1:15pm–3:00pm Part of Poster session 3 Multi-Omic Integration of Immunopeptidomics, Transcriptomics, and Proteomics to Quantify gp100 pHLA Presentation in Cutaneous Melanoma Board PS03.064 Clinical · Multi-omics
Regeneron Tarrytown, NY
regeneron.com Large pharma Biotechnology company that discovers, develops and markets antibody and other medicines.	Poster Tue Sep 29 1:15pm–3:00pm Part of Poster session 2 Comparative Evaluation of Electron-Based Dissociation Methods for O-Glycosylation Site Localization in Tn-Glycopeptides Exhibit Hall · Board PS02.079 PTMs & glyco · Methods Session Tue Sep 29 4:15pm–5:20pm Proteomics for Advanced Therapeutics Room 334-336 Drug discovery
Abvion Biologics Utrecht, Netherlands
abvion.bio Biotech Utrecht company, founded 2024, discovering therapeutic human antibodies by mass spectrometry-based de novo sequencing of antibodies straight from blood.	Plenary Tue Sep 29 4:15pm–5:20pm Part of Proteomics for Advanced Therapeutics Integrative Proteomics Enables Direct De Novo Sequencing of Polyclonal Antibodies from Human Biofluids Room 334-336 Drug discovery Collaborators: Utrecht University, Amsterdam UMC
Bayer Leverkusen, Germany
bayer.com Large pharma Pharmaceutical and life sciences company headquartered in Leverkusen, Germany.	Poster Tue Sep 29 1:15pm–3:00pm Part of Poster session 2 Longitudinal Deep Plasma Proteomics Reveals Molecular Signatures of Early ADPKD Disease Burden and Progression Trajectories Exhibit Hall · Board PS02.066 Clinical
Bertis Gwacheon, South Korea
bertis.com Biotech Korean proteomics-based diagnostics company developing blood tests for cancer, including the Mastocheck breast cancer test.	Poster Tue Sep 29 1:15pm–3:00pm Part of Poster session 2 msmu: A Computational Framework for Modular and Provenance-Aware LC-MS Proteomics Data Analysis Based on MuData Exhibit Hall · Board PS02.138 AI & data
B Bionsight
Biotech Korean drug discovery company using chemoproteomics and AI for target identification and off-target profiling.	Poster Wed Sep 30 1:15pm–3:00pm Part of Poster session 3 Eliminating Trypsin Carryover in High-Throughput Limited Proteolysis-Based Proteomic Profiling: Optimized Solid-Phase Extraction Enhances the Fidelity of Proteome-Wide Ligand Profiling Board PS03.042f Methods · Drug discovery Collaborators: Kangwon National University
NEOsphere Biotechnologies Martinsried, Germany
neospherebiotechnologies.com Biotech Drug discovery company using high-throughput proteomics to find molecular glue degraders and their protein targets.	Talk Mon Sep 28 10:30am–12:00pm Part of Chemical Proteomics + Drug Discovery 1 Discovery and validation of > 150 novel CRBN neosubstrates by high-throughput deep proteomic screening of molecular glue degrader libraries Nicoll 1 Drug discovery
Roche Basel, Switzerland
roche.com Large pharma Swiss pharmaceutical and diagnostics company headquartered in Basel.	Poster Wed Sep 30 1:15pm–3:00pm Part of Poster session 3 Cysteinome Profiling of Covalent Lead Compounds Board PS03.042b Drug discovery
Talus Bio Seattle, WA
talus.bio Biotech Drug discovery company in Seattle developing medicines against transcription factors, using proteomics to measure their activity.	Poster Wed Sep 30 1:15pm–3:00pm Part of Poster session 3 Regulome-Level Dissection of Transcription Factor Targeting Modalities to Characterize Mechanism of Action Board PS03.036 Drug discovery
MSD Rahway, NJ	○Grant Supporter
msd.com Large pharmaGrant Supporter Global pharmaceutical company, known as Merck & Co. in the US and Canada, developing medicines and vaccines.